We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+13.86%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$421M
AUM Growth
+$85.4M
Cap. Flow
+$55.9M
Cap. Flow %
13.26%
Top 10 Hldgs %
50.23%
Holding
96
New
22
Increased
24
Reduced
22
Closed
7

Top Buys

Rank Stock Value
1
NRIX icon
Nurix Therapeutics
NRIX
+$11.6M
2
RVMD icon
Revolution Medicines
RVMD
+$5.77M
3
PLX icon
Protalix BioTherapeutics
PLX
+$5.61M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.51M
5
ACET icon
Adicet Bio
ACET
+$4.41M

Top Sells

Rank Stock Value
1
FLNA
Filana Therapeutics
FLNA
+$3.07M
2
STIM icon
Neuronetics
STIM
+$2.91M
3
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$2.9M
4
AGTC
Applied Genetic Technologies Corporation
AGTC
+$2.46M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 90.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MASI
76
DELISTED
Masimo
MASI
$689K 0.16%
3,000
– –
MDGL icon
77
Madrigal Pharmaceuticals
MDGL
$11.7B
$655K 0.16%
5,600
-1,000
-15% -$117K
NXTC icon
78
NextCure
NXTC
$22.7M
$651K 0.15%
5,417
– –
SPPI
79
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$644K 0.15%
+197,500
New +$708K
XFOR icon
80
X4 Pharmaceuticals
XFOR
$427M
$602K 0.14%
+2,330
New +$612K
ISEE
81
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$556K 0.13%
89,951
+21,000
+30% +$127K
RDUS
82
DELISTED
Radius Health, Inc.
RDUS
$302K 0.07%
14,500
-7,500
-34% -$158K
NGM
83
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$291K 0.07%
+10,000
New +$280K
SCPH
84
DELISTED
scPharmaceuticals
SCPH
$259K 0.06%
38,891
– –
LCTX icon
85
Lineage Cell Therapeutics
LCTX
$277M
$177K 0.04%
75,400
-4,600
-6% -$11K
VRNA
86
DELISTED
Verona Pharma
VRNA
$153K 0.04%
18,337
-143,170
-89% -$1.19M
CNTB
87
Connect Biopharma Holdings
CNTB
$139M
$148K 0.04%
+8,000
New +$136K
BLUE
88
DELISTED
bluebird bio
BLUE
– –
-2,337
Closed -$1.31M
FLNA
89
Filana Therapeutics
FLNA
$46.8M
– –
-450,000
Closed -$3.07M
CNST
90
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-100,594
Closed -$2.9M
PAND
91
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
– –
-58,222
Closed -$865K
FSDC
92
DELISTED
FS Development Corp. Class A Common Stock
FSDC
– –
-150,000
Closed -$1.65M
PRVL
93
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
– –
-75,000
Closed -$1.73M
BEAT
94
DELISTED
BioTelemetry, Inc.
BEAT
– –
-5,200
Closed -$375K
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, DAFNA Capital Management held 96 positions worth $421M, up 25% from $336M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DAFNA Capital Management deployed $55.9M of net new capital in Q1 2021, opening 22 new positions and adding to 24 existing holdings. Its largest new stake was Nurix Therapeutics: 306,320 shares worth $9.52M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier.

On the sell side, the largest reduction was Neuronetics, an estimated $2.91M trimmed.

  • DAFNA Capital Management's largest Q1 2021 buy was Nurix Therapeutics: 306,320 shares worth $9.52M.
  • DAFNA Capital Management added most to Revolution Medicines in Q1 2021, an estimated $5.77M increase.
  • DAFNA Capital Management's biggest Q1 2021 reduction was Neuronetics, cutting an estimated $2.91M.
  • DAFNA Capital Management fully exited Filana Therapeutics in Q1 2021, selling an estimated $3.07M.
  • DAFNA Capital Management's ten largest holdings make up 50% of its $421M portfolio in Q1 2021.
  • DAFNA Capital Management opened 22 new positions and closed 7 in Q1 2021.
  • DAFNA Capital Management's portfolio value rose 25% quarter-over-quarter to $421M.

Based on DAFNA Capital Management's 13F filing for Q1 2021, filed 17 May 2021.